Pathogenesis of lassa fever

Nadezhda E. Yun, David Walker

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Lassa virus, an Old World arenavirus (family Arenaviridae), is the etiological agent of Lassa fever, a severe human disease that is reported in more than 100,000 patients annually in the endemic regions of West Africa with mortality rates for hospitalized patients varying between 5-10%. Currently, there are no approved vaccines against Lassa fever for use in humans. Here, we review the published literature on the life cycle of Lassa virus with the specific focus put on Lassa fever pathogenesis in humans and relevant animal models. Advancing knowledge significantly improves our understanding of Lassa virus biology, as well as of the mechanisms that allow the virus to evade the host's immune system. However, further investigations are required in order to design improved diagnostic tools, an effective vaccine, and therapeutic agents.

Original languageEnglish (US)
Pages (from-to)2031-2048
Number of pages18
JournalViruses
Volume4
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Lassa Fever
Lassa virus
Old World Arenaviruses
Arenaviridae
Vaccines
Western Africa
Life Cycle Stages
Immune System
Animal Models
Viruses
Mortality
Therapeutics

Keywords

  • Arenavirus
  • Cell-mediated immunity
  • Lassa virus
  • Pathogenesis

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Pathogenesis of lassa fever. / Yun, Nadezhda E.; Walker, David.

In: Viruses, Vol. 4, No. 10, 10.2012, p. 2031-2048.

Research output: Contribution to journalArticle

Yun, Nadezhda E. ; Walker, David. / Pathogenesis of lassa fever. In: Viruses. 2012 ; Vol. 4, No. 10. pp. 2031-2048.
@article{0c8b558287e545758a49a79ca4da6e0f,
title = "Pathogenesis of lassa fever",
abstract = "Lassa virus, an Old World arenavirus (family Arenaviridae), is the etiological agent of Lassa fever, a severe human disease that is reported in more than 100,000 patients annually in the endemic regions of West Africa with mortality rates for hospitalized patients varying between 5-10{\%}. Currently, there are no approved vaccines against Lassa fever for use in humans. Here, we review the published literature on the life cycle of Lassa virus with the specific focus put on Lassa fever pathogenesis in humans and relevant animal models. Advancing knowledge significantly improves our understanding of Lassa virus biology, as well as of the mechanisms that allow the virus to evade the host's immune system. However, further investigations are required in order to design improved diagnostic tools, an effective vaccine, and therapeutic agents.",
keywords = "Arenavirus, Cell-mediated immunity, Lassa virus, Pathogenesis",
author = "Yun, {Nadezhda E.} and David Walker",
year = "2012",
month = "10",
doi = "10.3390/v4102031",
language = "English (US)",
volume = "4",
pages = "2031--2048",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - Pathogenesis of lassa fever

AU - Yun, Nadezhda E.

AU - Walker, David

PY - 2012/10

Y1 - 2012/10

N2 - Lassa virus, an Old World arenavirus (family Arenaviridae), is the etiological agent of Lassa fever, a severe human disease that is reported in more than 100,000 patients annually in the endemic regions of West Africa with mortality rates for hospitalized patients varying between 5-10%. Currently, there are no approved vaccines against Lassa fever for use in humans. Here, we review the published literature on the life cycle of Lassa virus with the specific focus put on Lassa fever pathogenesis in humans and relevant animal models. Advancing knowledge significantly improves our understanding of Lassa virus biology, as well as of the mechanisms that allow the virus to evade the host's immune system. However, further investigations are required in order to design improved diagnostic tools, an effective vaccine, and therapeutic agents.

AB - Lassa virus, an Old World arenavirus (family Arenaviridae), is the etiological agent of Lassa fever, a severe human disease that is reported in more than 100,000 patients annually in the endemic regions of West Africa with mortality rates for hospitalized patients varying between 5-10%. Currently, there are no approved vaccines against Lassa fever for use in humans. Here, we review the published literature on the life cycle of Lassa virus with the specific focus put on Lassa fever pathogenesis in humans and relevant animal models. Advancing knowledge significantly improves our understanding of Lassa virus biology, as well as of the mechanisms that allow the virus to evade the host's immune system. However, further investigations are required in order to design improved diagnostic tools, an effective vaccine, and therapeutic agents.

KW - Arenavirus

KW - Cell-mediated immunity

KW - Lassa virus

KW - Pathogenesis

UR - http://www.scopus.com/inward/record.url?scp=84868146851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868146851&partnerID=8YFLogxK

U2 - 10.3390/v4102031

DO - 10.3390/v4102031

M3 - Article

VL - 4

SP - 2031

EP - 2048

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 10

ER -